Medical isotope developer ARTMS of British Columbia, Canada, announced that its cyclotron-produced technetium-99m (Tc-99m) radioisotope is being shipped commercially following approval on November 26 for clinical use by Health Canada.

The application for approval by Health Canada was supported by a joint filing from ARTMS, BC Cancer, the TRIUMF particle accelerator center in Canada, Lawson Health Research, and the Centre for Probe Development and Commercialization.

In a statement about the approval, ARTMS said that its cyclotron-based technology provides a badly needed alternative source to Tc-99m that generators produced in a small numbers of nuclear reactors globally. This helps prevent shortages when operations at generators are disrupted, ARTMS said.

To read more please visit:

https://www.auntminnie.com/index.aspx?sec=ser&sub=def&pag=dis&ItemID=131195